Literature DB >> 11522615

Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts.

K Rombouts1, A Wielant, K Hellemans, D Schuppan, A Geerts.   

Abstract

1. Previous in vivo studies in men and experimental animal models have shown that hyperaldosteronemia is correlated with cardiac fibrosis due to increased total collagen synthesis. As yet, it is unclear whether aldosterone has direct pro-fibrogenic effect on cardiac fibroblasts, the fibrogenic effector cell in the myocardium, and if so which procollagens specifically are synthesized at higher rates. 2. The present study aims at establishing whether de novo collagen synthesis by cardiac fibroblasts is enhanced following exposure for 2x24 h to pharmacological (10(-7) - 10(-8) M), near-physiological (10(-9) M) or physiological (10(-10) - 10(-11) M) aldosterone concentrations. During the last 24 h, cells were metabolically labelled with [35S]-methionine/[35S]-cysteine. Labelled procollagens were immunoprecipitated quantitatively using antibodies against specific procollagens. Contrary to expectations, 10(-7) M aldosterone inhibited significantly de novo synthesis of procollagens type I and IV (-35% and -42%, respectively). For procollagen type III, only a tendency towards inhibition was observed. At lower concentrations of aldosterone (10(-8) - 10(-10) M), synthesis of procollagens type I, III or IV was unaffected. 3. Cellular DNA synthesis under influence of aldosterone was evaluated by measuring BrdU incorporation. Cells were treated with aldosterone, while BrdU was added during the last 16 h of treatment. Aldosterone had no demonstrable effect on cellular proliferation. 4. Reverse transcription-polymerase chain reaction (RT - PCR) clearly demonstrated the presence of mineralocorticoid receptor mRNA in cardiac fibroblasts. 5. In spite of the expression of the mineralocorticoid receptor by cultured cardiac fibroblasts, the pro-fibrogenic effect of aldosterone as observed in vivo, is not likely to be due to a direct effect of this hormone in cardiac fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522615      PMCID: PMC1572936          DOI: 10.1038/sj.bjp.0704247

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.

Authors:  J L Arriza; C Weinberger; G Cerelli; T M Glaser; B L Handelin; D E Housman; R M Evans
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

2.  Quantitative study of tissue collagen metabolism.

Authors:  S Takahashi; M J Lee
Journal:  Anal Biochem       Date:  1987-05-01       Impact factor: 3.365

3.  Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice.

Authors:  K Haseroth; D Gerdes; S Berger; M Feuring; A Günther; C Herbst; M Christ; M Wehling
Journal:  Biochem Biophys Res Commun       Date:  1999-12-09       Impact factor: 3.575

4.  Heavy metal intensification of DAB-based HRP reaction product.

Authors:  J C Adams
Journal:  J Histochem Cytochem       Date:  1981-06       Impact factor: 2.479

5.  All-trans and 9-cis retinoic acid alter rat hepatic stellate cell phenotype differentially.

Authors:  K Hellemans; I Grinko; K Rombouts; D Schuppan; A Geerts
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

6.  Glucocorticoid receptors and inhibition of neonatal mouse dermal fibroblast growth in primary culture.

Authors:  L A Verbruggen; D S Salomon
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

7.  Serum concentration of the aminoterminal procollagen type III peptide in the rat reflects early formation of connective tissue in experimental liver cirrhosis.

Authors:  D Schuppan; J M Dumont; K Y Kim; G Hennings; E G Hahn
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

8.  Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts.

Authors:  R Raghow; A E Postlethwaite; J Keski-Oja; H L Moses; A H Kang
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

9.  Glucocorticoids alter the ratio of type III type I collagen synthesis by mouse dermal fibroblasts.

Authors:  L A Verbruggen; S Abe
Journal:  Biochem Pharmacol       Date:  1982-05-01       Impact factor: 5.858

10.  Relationship of cell growth to collagen synthesis in glucocorticoid treated A/J and C57BL6/J neonatal mouse dermal fibroblasts.

Authors:  L A Verbruggen; S Orloff; V H Rao; D S Salomon
Journal:  Scand J Rheumatol       Date:  1983       Impact factor: 3.641

View more
  7 in total

Review 1.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

2.  Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells.

Authors:  Hendrik Reynaert; Krista Rombouts; Yutao Jia; Daniel Urbain; Nirjhar Chatterjee; Naoki Uyama; Albert Geerts
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 3.  Aldosterone: a risk factor for vascular disease.

Authors:  Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

4.  Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.

Authors:  H Reynaert; K Rombouts; A Vandermonde; D Urbain; U Kumar; P Bioulac-Sage; M Pinzani; J Rosenbaum; A Geerts
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

5.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

Authors:  Michael Gekle; Claudia Grossmann
Journal:  Pflugers Arch       Date:  2008-11-19       Impact factor: 3.657

6.  Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism.

Authors:  Chi-Sheng Hung; Yi-Lwun Ho; Yi-Yao Chang; Vin-Cent Wu; Xue-Ming Wu; Jen-Kuang Lee; Shih-Chieh Chueh; Yen-Hung Lin; Yuan-Shian Changh; Shao-Yu Yang; Ya-Hui Hu; Ming-Jai Sui; Ming-Fong Chen; Kwan-Dun Wu
Journal:  ScientificWorldJournal       Date:  2013-12-29

7.  Spironolactone (an adjuvant therapy) in rheumatoid arthritis: a case control study.

Authors:  Harpreet Singh; Saroj Bala; Deepak Jain; Ruchi Jagota; Rekha Mathur
Journal:  Reumatologia       Date:  2018-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.